We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Field Application of a New CSF Vaccine Based on Plant-Produced Recombinant E2 Marker Proteins on Pigs in Areas with Two Different Control Strategies.
- Authors
Oh, Yeonsu; Park, Youngmin; Choi, Bo-Hwa; Park, Soohong; Gu, Sungmin; Park, Jungae; Kim, Jong-Kook; Sohn, Eun-Ju
- Abstract
A classical swine fever virus (CSFV)-modified live LOM (low-virulence strain of Miyagi) vaccine (MLV-LOM) to combat CSF has been used in places where the disease is prevalent around the world, including in Korea, except in Jeju Island. In general, modified live virus-based vaccines (MLV) are known to be highly effective in inducing immune responses. At the same time, MLVs also have potential dangers such as a circulation in the field. There is still a need for safer and more effective vaccines to control CSF in the field. In this study, we applied a new CSF vaccine based on plant-produced recombinant E2 marker proteins at two different locations, Jeju Island and a suburb of Pohang, using different CSF control strategies. The result suggested that vaccinated sows in Jeju Island highly developed immunogenicity and maintained stably until 102 days post-vaccination (dpv). Its piglets that received maternal antibodies were shown to carry high serological values and maintained them until 40 days of age, which was the end of the follow-up. Naïve piglets vaccinated at 40 days of age showed high serological values and these were maintained until 100 days of age (60 dpv), which was the end of the follow-up. The vaccine was also effective in inducing immune responses in newborn piglets that carried maternal antibodies received from MLV-LOM vaccine-immunized mother sows.
- Subjects
CHEJU Island (Korea); MIYAGI-ken (Japan); MATERNALLY acquired immunity; VACCINE effectiveness; CLASSICAL swine fever virus; SWINE; VACCINATION; VACCINES
- Publication
Vaccines, 2021, Vol 9, Issue 6, p537
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines9060537